Almirall and IRB Barcelona team up to tackle skin disease
pharmaphorum
JANUARY 18, 2022
The use of monovalent degraders, which enable the targeted degradation of disease-relevant proteins, offers a new avenue to reach tissue that cannot be targeted with conventional therapeutic agents.
Let's personalize your content